Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Fosfocreatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfocreatine SCHEMBL9319928 | 0.96 | — | — | |
| Fosfocreatine SCHEMBL3026727 | 0.96 | — | — | |
| Fosfocreatine SCHEMBL30173229 | 0.88 | — | — | |
| Fosfocreatine SCHEMBL30031412 | 0.86 | MVD (0.38) | — | |
| Fosfocreatine SCHEMBL1640494 | 0.86 | MVD (0.38) | — | |
| Fosfocreatine SCHEMBL30930087 | 0.84 | MVD (0.37) | — | |
| Fosfocreatine SCHEMBL31181876 | 0.84 | MVD (0.37) | — | |
| Creatine SCHEMBL1065566 | 0.74 | NOS3 (0.39) | — | |
| Creatine SCHEMBL939498 | 0.73 | CA1 (0.37) | — | |
| Fosfocreatine SCHEMBL29749874 | 0.72 | MVD (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112159833-B | Reagent for eliminating endogenous glucose interference and application and method thereof | 三诺生物传感股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-101288649-B | Preparation technique of sodium phosphocreatine powder and injection preparation | SHANGHAI CIRUI MEDICAL TECHNOLOGY CO LTD | 2011-01-12 | — | — | CN | claimed |
| CN-101313910-B | Preparation technique for sodium phosphocreatine freeze-dried injection | SHANGHAI CRMED SCIENCE CO LTD | 2010-11-03 | — | — | CN | claimed |
| CN-101313910-A | Preparation technique for sodium phosphocreatine freeze-dried injection | SHANGHAI CRMED SCIENCE CO LTD (CN) | 2008-12-03 | — | — | CN | claimed |
| CN-101288649-A | Preparation technique of sodium phosphocreatine powder and injection preparation | SHANGHAI CIRUI MEDICAL SCI TEC (CN) | 2008-10-22 | — | — | CN | claimed |
| EP-0222257-A2 | A phosphocreatine containing pharmaceutical composition and method for preparing the same | SCHIAPPARELLI FARMACEUTICI S.p.A. (IT) | 1987-05-20 | — | — | EP | claimed |
| EP-4649083-A1 | COMPOUNDS DERIVED FROM DIHYDROPIRIDINES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHOD OF TREATMENT OF MUSCLE DISORDERS COMPRISING ADMINISTRATION OF SAID COMPOSITIONS | Universidad de Chile (CL) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024150029-A1 | COMPOUNDS DERIVED FROM DIHYDROPIRIDINES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHOD OF TREATMENT OF MUSCLE DISORDERS COMPRISING ADMINISTRATION OF SAID COMPOSITIONS | UNIVERSIDAD DE CHILE (CL) | 2024-07-18 | — | — | WO | disclosed |
| CN-111690612-B | Method for amplifying human neural precursor cells by modulating Wnt signaling and/or Notch signaling | 同济大学 | 2023-07-25 | — | — | CN | disclosed |
| US-20230173110-A1 | NON-HUMAN MAMMAL MODEL OF HUMAN DEGENERATIVE DISORDER, USES THEREOF, AND METHOD OF TREATING HUMAN DEGENERATIVE DISORDER | UNIVERSITY OF ROCHESTER | 2023-06-08 | — | — | US | disclosed |
| US-11596700-B2 | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder | UNIVERSITY OF ROCHESTER (US) | 2023-03-07 | — | — | US | disclosed |
| CN-112159833-B | Reagent for eliminating endogenous glucose interference and application and method thereof | 三诺生物传感股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115432680-A | Method for rapidly synthesizing hydroxyapatite ultra-long nanowire with high biocompatibility and high bioactivity by microwaves | 中国科学院上海硅酸盐研究所 | 2022-12-06 | — | — | CN | disclosed |
| WO-2002078745-A2 | USE OF MGLUR5 ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF AUTISM, MENTAL RETARDATION, SCHIZOPHRENIA | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020045564-A1 | Methods of modulating muscle contraction | VAN EYK JENNIFER E (CA) | 2002-04-18 | — | — | US | disclosed |
| US-6248549-B1 | DRUG SCREENING FOR MODULATORS OF P21 ACTIVATED KINASE; CONTACTING INDICATOR COMPOSITION LIKE SMOOTH MUSCLE OR CARDIAC MUSCLE CELL EXTRACT WITH TEST AGENT AND DETERMINING EFFECT ON ENYZME ACTIVITY | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-06-19 | — | — | US | disclosed |
| US-5302520-A | Enzymatic synthesis of isotopically labeled carbohydrates | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-04-12 | — | — | US | disclosed |
| US-5227296-A | ENZYMATIC SYNTHESIS OF ISOTOPICALLY LABELED CARBOHYDRATES, NUCLEOTIDES AND CITRIC ACID INTERMEDIATES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-07-13 | — | — | US | disclosed |
| WO-1992005270-A2 | ENZYMATIC SYNTHESIS OF ISOTOPICALLY LABELED CARBOHYDRATES, NUCLEOTIDES AND CITRIC ACID INTERMEDIATES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-04-02 | — | — | WO | disclosed |
| EP-0222257-A2 | A phosphocreatine containing pharmaceutical composition and method for preparing the same | SCHIAPPARELLI FARMACEUTICI S.p.A. (IT) | 1987-05-20 | — | — | EP | disclosed |